Hyperion Therapeutics (HPTX) Tops Q4 EPS by 67c

Hyperion Therapeutics (NASDAQ: HPTX) reported Q4 EPS of $0.47, $0.67 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $24.6 million.

Hyperion Therapeutics sees FY2015 revenue of $120-128 million, versus the consensus of $119.33 million.

"2014 was another momentous year of growth for us as we continued to make great inroads toward increasing the number of UCD patients treated with RAVICTI," said Donald J. Santel, president and chief executive officer. "We have delivered strong quarter over quarter financial results, and importantly, we have contributed to the body of knowledge regarding the optimal treatment of UCDs via publication of data from our clinical trials."

Santel added, "As 2015 progresses, we will further expand our base business by continuing our education efforts to patients and physicians to improve outcomes for UCD patients. We expect to receive a decision from the European Medicines Agency on our Marketing Authorization Application for RAVICTI by year-end, begin our Phase 3 clinical trial in hepatic encephalopathy in the second half of 2015, and finally, a continued priority for us is increasing shareholder value by broadening our pipeline."

For earnings history and earnings-related data on Hyperion Therapeutics (HPTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c